The Israeli data that nukes the Pfizer vaccine: What did Pfizer know and when did they know it?
Friday February 25, 2022

Last year, Philip Dormitzer, the chief scientific officer at Pfizer, described Israel as “a sort of laboratory” to “see the effect” of his company’s vaccines. Well, it took over a year into the vaccine drive that injected most Israelis with three shots and some with four to finally publish information on adverse events. What Israel published earlier this month based on a health ministry survey of 2,049 people who got booster shots is not only damning, but unmistakably revealing that there is no way Pfizer did not see these adverse events during the clinical trials in 2020. What did they know and when did they know it?
On Feb. 10, the Israeli Health Ministry published (English version here) the results of a survey of adverse events among roughly 2,000 random Israelis who received booster shots. It’s shocking that it took this long for them to conduct such a survey and didn’t do this a year ago, but it’s better late than never. Just the top-line numbers from the survey should alarm us all. A total of 75% of women and 58% of men reported experiencing at least one side effect within the 21- to 30-day follow-up period of the interview. Obviously, the majority of these were minor, but 51% of the women and 35% of the men who experienced a side effect reported that as a result, they had difficulty performing daily activities.
Full stop right there. Even before we get into more serious problems. Just the fact that the shot knocked out such a massive percentage of people clearly violates the informed consent through which the shots were marketed and most certainly makes any mandate immoral. Right off the bat, it’s clear that this is not like taking a vitamin D pill. Moreover, the fact that we have zero long-term studies, but such a massive percentage get at least a sick feeling from it in the short run should concern everyone. Again, why wasn’t such a survey done in January 2021 after the first dose?
read on...